Tags

Type your tag names separated by a space and hit enter

The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity.
Virology. 2001 Apr 10; 282(2):278-87.V

Abstract

Sequence variants of the Epstein-Barr virus (EBV)-encoded latent membrane protein-1 (LMP1) have been reported in association with EBV-linked malignancies but little is known about their effects on signalling pathways and phenotype. We have examined the ability of the nasopharyngeal carcinoma (NPC)-derived variant, CAO-LMP1 to activate the transcription factors NF-kappaB and AP-1 in epithelial cells. In this study, transient expression of CAO-LMP1 was found to activate higher levels of NF-kappaB and AP-1 than the prototype B95.8-LMP1 in human embryonic kidney (HEK) 293 cells and SV40-transformed keratinocytes (SVK). In addition, pulse-chase analysis revealed that CAO-LMP1 has a longer half-life than B95.8-LMP1. Chimera studies localised these phenomena to the transmembrane domains of CAO-LMP1, suggesting that this enhanced signalling capacity may be a consequence of its prolonged half-life. The ability of CAO-LMP1 to activate higher levels of NF-kappaB and AP-1 may contribute to its potent transforming properties.

Authors+Show Affiliations

CRC Institute for Cancer Studies, The University of Birmingham Medical School, Vincent Drive, Birmingham, Edgbaston, B15 2TT, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11289810

Citation

Blake, S M., et al. "The Transmembrane Domains of the EBV-encoded Latent Membrane Protein 1 (LMP1) Variant CAO Regulate Enhanced Signalling Activity." Virology, vol. 282, no. 2, 2001, pp. 278-87.
Blake SM, Eliopoulos AG, Dawson CW, et al. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology. 2001;282(2):278-87.
Blake, S. M., Eliopoulos, A. G., Dawson, C. W., & Young, L. S. (2001). The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology, 282(2), 278-87.
Blake SM, et al. The Transmembrane Domains of the EBV-encoded Latent Membrane Protein 1 (LMP1) Variant CAO Regulate Enhanced Signalling Activity. Virology. 2001 Apr 10;282(2):278-87. PubMed PMID: 11289810.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. AU - Blake,S M, AU - Eliopoulos,A G, AU - Dawson,C W, AU - Young,L S, PY - 2001/4/6/pubmed PY - 2001/5/22/medline PY - 2001/4/6/entrez SP - 278 EP - 87 JF - Virology JO - Virology VL - 282 IS - 2 N2 - Sequence variants of the Epstein-Barr virus (EBV)-encoded latent membrane protein-1 (LMP1) have been reported in association with EBV-linked malignancies but little is known about their effects on signalling pathways and phenotype. We have examined the ability of the nasopharyngeal carcinoma (NPC)-derived variant, CAO-LMP1 to activate the transcription factors NF-kappaB and AP-1 in epithelial cells. In this study, transient expression of CAO-LMP1 was found to activate higher levels of NF-kappaB and AP-1 than the prototype B95.8-LMP1 in human embryonic kidney (HEK) 293 cells and SV40-transformed keratinocytes (SVK). In addition, pulse-chase analysis revealed that CAO-LMP1 has a longer half-life than B95.8-LMP1. Chimera studies localised these phenomena to the transmembrane domains of CAO-LMP1, suggesting that this enhanced signalling capacity may be a consequence of its prolonged half-life. The ability of CAO-LMP1 to activate higher levels of NF-kappaB and AP-1 may contribute to its potent transforming properties. SN - 0042-6822 UR - https://www.unboundmedicine.com/medline/citation/11289810/The_transmembrane_domains_of_the_EBV_encoded_latent_membrane_protein_1__LMP1__variant_CAO_regulate_enhanced_signalling_activity_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0042-6822(01)90828-1 DB - PRIME DP - Unbound Medicine ER -